Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have been diagnosed with cancer of the ureter, confirmed by a scope procedure (ureteroscopy) and imaging scans (such as CT, MRI, or PET-CT), with no signs that the cancer has spread to other parts of the body
• People whose biopsy results show that more than half of the cancer tissue is a type called urothelial carcinoma
• People whose medical team has determined that a specific surgical procedure to remove part of the ureter and reconnect the urinary system is appropriate and planned for them
• People whose expected survival is more than 12 weeks
• People who have a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities independently)
• People who agree to provide blood, urine, and tissue samples for laboratory testing during the trial
• People whose blood cell counts, liver function, and kidney function meet specific minimum levels set by the trial (confirm with trial site for exact values)
• People who are willing to take part and are able to follow the study requirements

Who may not be able to join:

• People who currently have another active cancer in a different part of the body (people with a previous cancer that has been treated and is now stable may still be considered)
• People who have urothelial cancer affecting both ureters
• People who also have urothelial cancer in the kidney's collecting area (renal pelvis) or in the bladder, unless it is an early-stage bladder cancer that can be fully removed by a standard bladder procedure
• People who have received a live vaccine within 4 weeks before starting the trial, or who plan to receive one during the study
• People who have an active or known autoimmune disease (a condition where the immune system attacks the body)
• People with a known history of a primary immune system deficiency
• People who have previously received an organ transplant or a bone marrow/stem cell transplant from another person
• People who are pregnant or breastfeeding
• People with untreated active Hepatitis B or Hepatitis C infection (people receiving antiviral treatment and whose virus levels are being monitored may be considered at the treating doctor's discretion)
• People who have been taking immune-suppressing medications within 4 weeks before starting the trial, with some exceptions for low-dose or topical steroids (confirm with trial site)
• People with a known allergy to either of the study medications, Tislelizumab or Nab-Paclitaxel
• People with active tuberculosis
• People who have previously been treated with certain types of immunotherapy drugs (PD-1, PD-L1, or CTLA-4 inhibitors)
• People who are currently taking part in another clinical trial
• People who are capable of having children and are not using effective contraception
• People with certain serious uncontrolled health conditions, including HIV infection, severe uncontrolled infections, uncontrolled heart or lung or liver or kidney disease, severe neurological or psychiatric conditions, uncontrolled high blood pressure, active bleeding or new blood clotting problems, or kidney failure requiring dialysis

Important: Always verify eligibility with the trial site directly before applying.